<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038687</url>
  </required_header>
  <id_info>
    <org_study_id>09-006618</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01038687</nct_id>
  </id_info>
  <brief_title>Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation</brief_title>
  <official_title>Effects of A3309, an Ileal Bile Acid Transport Inhibitor, on Gastrointestinal and Colonic Motor Functions in Female Patients With Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Camilleri, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose&#xD;
      response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on&#xD;
      gastric, intestinal and colonic transit in patients with functional constipation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study period Estimated date of first patient enrolled: January 2010 Study design This is a&#xD;
      single-center, randomized, parallel group, double-blind, placebo-controlled, dose response,&#xD;
      pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric,&#xD;
      intestinal and colonic transit in patients with functional constipation. Doses of 10 or 20 mg&#xD;
      A3309 or matching placebo will be administered orally once daily for fourteen (14)&#xD;
      consecutive days.&#xD;
&#xD;
      Aim To assess the dose related effects of A3309 on small bowel and overall colonic transit&#xD;
      and bowel function in patients with functional constipation.&#xD;
&#xD;
      Number of patients planned Twelve completed female patients with functional constipation in&#xD;
      each treatment group for a total of 36 patients.&#xD;
&#xD;
      Diagnosis and main eligibility criteria Female patients with diagnosed functional&#xD;
      constipation will be recruited from the local community by public advertisement placed within&#xD;
      areas of Mayo Clinic or by a targeted mailing of an informational letter.&#xD;
&#xD;
      Methodology Patients with functional constipation will be screened for eligibility and&#xD;
      informed about the study during pre-screening dialogue and also at the initial Visit 1&#xD;
      screen.&#xD;
&#xD;
      Within seven (7) to fourteen (14) days of Visit 1, eligible patients will return for an&#xD;
      abbreviated scintigraphy test with images obtained only at 4 and 24 hours following In111&#xD;
      capsule ingestion. A geometric center at 24 hours must be less than or equal to 2.30 to&#xD;
      qualify for randomization to study medication. The assigned medication is either 10 or 20 mg&#xD;
      A3309 or placebo administered orally once daily for fourteen (14) consecutive days. The&#xD;
      allocation to treatment group will be concealed.&#xD;
&#xD;
      A urine pregnancy test will be performed for all females of child bearing potential at Visit&#xD;
      1 and again within the 48 hours prior to the receipt of the isotopes by mouth for both the&#xD;
      abbreviated and post-study medication transit scintigraphy tests at Visit 2 and Visit 4. Note&#xD;
      that females who are status post-bilateral tubal ligation, hysterectomy or postmenopausal are&#xD;
      exempted from this test.&#xD;
&#xD;
      Patients will take study medication at home for eleven (11) consecutive days. Study&#xD;
      medication will be administered at the Charlton 7 Clinical Research Unit (CRU) at Visit 4, 5,&#xD;
      and 6, the days of scintigraphic assessment of gastric, small bowel and colonic transit of&#xD;
      solids performed over a 48 hour period for a total dosing period of fourteen (14) consecutive&#xD;
      days.&#xD;
&#xD;
      Within seven (7) to ten (10) days of Visit 6, patients will return to the Charlton 7 CRU for&#xD;
      final safety monitoring and an exit physical examination and interview with study staff.&#xD;
&#xD;
      Investigational product, dosage and mode of administration&#xD;
&#xD;
      Patients will take 15 or 20 mg of A3309 or placebo administered orally for eleven (11)&#xD;
      consecutive days and report for post-study medication transit scintigraphy on day twelve (12)&#xD;
      of dosing. Study medication will be administered once with the In111 capsule on Visit 4 and&#xD;
      once immediately before the camera images obtained on Visits 5 and 6. Study medication will&#xD;
      be administered at Charlton 7 CRU by a nurse on days 12-14.&#xD;
&#xD;
      Duration of treatment&#xD;
&#xD;
      A3309 or matching placebo will be administered orally once daily for fourteen (14)&#xD;
      consecutive days.&#xD;
&#xD;
      Duration of patients' involvement in the study&#xD;
&#xD;
      Each patient will attend seven (7) visits at the clinic during a period of about thirty-one&#xD;
      (31) to forty-one (41) days.&#xD;
&#xD;
      Efficacy assessments&#xD;
&#xD;
        -  Scintigraphic small bowel and colonic transit&#xD;
&#xD;
        -  Assessment of stool frequency and consistency using the Bowel Pattern Diary&#xD;
&#xD;
      Pharmacokinetic analysis Blood samples for analysis of pharmacokinetic (PK) parameters will&#xD;
      be collected at Visit 4, before dosing and at 30, 60, 90, 120, 150, 180, 210, and 240 minutes&#xD;
      post-dose. PK parameters will be analyzed.&#xD;
&#xD;
      Safety assessments&#xD;
&#xD;
      The following safety assessments will be performed:&#xD;
&#xD;
        -  Laboratory safety tests, including a complete blood count (CBC), a comprehensive&#xD;
           metabolic panel (CMP), coagulation studies (PT and APTT) and a urinalysis (UA) performed&#xD;
           at Visit 1 study entry, Visit 6 completion of transit scintigraphy and final dose of&#xD;
           study medication, and Visit 7 study completion. A urine screen for drugs of abuse will&#xD;
           be performed once at Visit 1 study entry.&#xD;
&#xD;
        -  A 12-lead ECG performed at Visit 1 study entry, Visit 6 completion of post-study&#xD;
           medication transit scintigraphy and Visit 7 study completion.&#xD;
&#xD;
        -  A physical examination by a study physician at Visit 1 study entry and Visit 7 study&#xD;
           completion.&#xD;
&#xD;
        -  Vital signs (including temperature, pulse, blood pressure and respiration rate) at every&#xD;
           visit&#xD;
&#xD;
        -  Urine pregnancy tests performed at Visit 1 study entry and within 48 hours prior to&#xD;
           receipt of radiation during the abbreviated transit scintigraphy and post-study&#xD;
           medication transit scintigraphy at Visit 2 and Visit 4, respectively&#xD;
&#xD;
        -  Interview for concomitant medications and adverse events at every visit&#xD;
&#xD;
      Statistical methods An analysis of covariance (ANCOVA) will be used to compare transit&#xD;
      parameters among the treatment groups. The co-variates considered for inclusion in the&#xD;
      analyses are age and body mass index (BMI). If necessary a suitable transformation for&#xD;
      potential skewness in the distributions of measured volumes may be used (e.g., ANCOVA on&#xD;
      ranks or log volumes).&#xD;
&#xD;
      If ANCOVA shows a p value less than or equal to 0.10, then both the 10 mg and 20 mg doses&#xD;
      will be compared to placebo (p value less than or equal to 0.025 to correct for 2 pairwise&#xD;
      comparisons by Dunnett's Test). Since each of the secondary endpoints assesses a separate&#xD;
      hypothesis regarding the effects of A3309, no adjustment in the alpha level for testing&#xD;
      multiple types of endpoints is anticipated, and a two-sided significance level of 0.05 will&#xD;
      be used in each ANCOVA model.&#xD;
&#xD;
      Statistical Power Based on data acquired using the same methods in the laboratory, the sample&#xD;
      size of 12 patients per group provides 80% power to detect differences of approximately 27%&#xD;
      to 37% in colonic transit at 24 hours, the primary endpoint. This magnitude of change is&#xD;
      considered clinically significant.&#xD;
&#xD;
      PK analyses Plasma concentration vs time curves will be plotted for each subject, on both&#xD;
      linear/linear and log10/linear scales. Mean plasma concentration vs time curves will also be&#xD;
      presented by dose level. Summary statistics (n, mean, SD, minimum, median, maximum, geometric&#xD;
      mean, and coefficient of variation) will be calculated for plasma concentrations at each time&#xD;
      point by dose level.&#xD;
&#xD;
      Summary statistics (n, mean, SD, minimum, median, maximum, geometric mean and coefficient of&#xD;
      variation) will be presented for all pharmacokinetic parameters by dose level. Geometric mean&#xD;
      and coefficient of variation will not be calculated for Tmax. The coefficient of variation&#xD;
      will be calculated using the following formula: CV(%) =[exp(SD2)-1]1/2 * 100 where&#xD;
      SD=standard deviation of the natural-logarithmically-transformed data.&#xD;
&#xD;
      Analysis data sets The primary analyses will follow the intent to treat (ITT) paradigm with&#xD;
      all patients randomized included in the analyses. Those patients with missing response values&#xD;
      will have their missing values imputed via the overall (patients with non-missing data) mean&#xD;
      and a corresponding adjustment in the ANCOVA residual error variance degrees of freedom&#xD;
      (subtracting one for each missing value imputed).&#xD;
&#xD;
      Safety data will be presented for all patients receiving investigational product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Transit at 24 Hours</measure>
    <time_frame>24 hours post-radiolabeled meal</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling</measure>
    <time_frame>6 hours post-radiolabeled meal</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic filling was measured by scintigraphy as the percentage of the radiolabeled meal that reached the colon at 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying , T1/2</measure>
    <time_frame>post-treatment, approximately 12-14 days</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Gastric emptying (GE t 1/2) was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the stomach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending Colon Emptying t 1/2</measure>
    <time_frame>post-treatment, approximately 12-14 days</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Ascending colon emptying t 1/2 was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the ascending colon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit at 8 Hours</measure>
    <time_frame>8 hours post-radiolabeled meal</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit at 48 Hours</measure>
    <time_frame>48 hours post-radiolabeled meal</time_frame>
    <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>14 days</time_frame>
    <description>Subjects maintained a validated daily bowel diary and recorded the number of bowel movements each day during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency</measure>
    <time_frame>14 days</time_frame>
    <description>Subjects maintained a validated daily bowel diary during treatment and recorded stool consistency according to the Bristol Stool Form Scale, where: 1= separate hard lumps; 2= lumpy sausage-shape; 3= cracked sausage; 4= smooth and soft sausage; 5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Effectiveness of A3309</measure>
    <time_frame>Day 14</time_frame>
    <description>Subject perception of treatment efficacy was measured using a 5 point numerical scale where 1=not at all effective to 5=extremely effective.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>A3309 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3309 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A3309</intervention_name>
    <description>A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
    <arm_group_label>A3309 15 mg</arm_group_label>
    <arm_group_label>A3309 20 mg</arm_group_label>
    <other_name>Elobixibat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Females aged 18 to 65 years old inclusive&#xD;
&#xD;
          2. A diagnosis of functional constipation as defined by two or more of the following:&#xD;
&#xD;
               1. fewer than three spontaneous complete bowel movements per week&#xD;
&#xD;
               2. hard or lumpy stools more than 25 % of the time&#xD;
&#xD;
               3. straining during a bowel movement more than 25 % of the time&#xD;
&#xD;
          3. A normal rectal exam result on file within the past 2 years or performed at screen to&#xD;
             exclude the possibility of an evacuation disorder. Examination must exclude findings&#xD;
             suggestive of an evacuation disorder such as high sphincter tone at rest, failure of&#xD;
             perineal descent and spasm, tenderness or paradoxical contraction of the puborectalis&#xD;
             muscles.&#xD;
&#xD;
          4. Females of child-bearing potential (those who have not experienced a bilateral tubal&#xD;
             ligation, hysterectomy or menopause) must use an acceptable method of contraception&#xD;
             during the study. Acceptable methods are surgical sterilization, hormonal methods such&#xD;
             as oral contraceptives, Norplant and Depo-Provera, double barrier method such as a&#xD;
             condom and spermicide, and an IUD.&#xD;
&#xD;
             Abstinent females may participate if they agree to use the double barrier method&#xD;
             should they become sexually active during the study.&#xD;
&#xD;
          5. Able to provide written informed consent prior to any study procedures being performed&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Female patients who are pregnant or breast feeding&#xD;
&#xD;
          2. Structural or metabolic diseases/conditions that affect the gastrointestinal system or&#xD;
             functional gastrointestinal disorders other than constipation. The long version BDQ&#xD;
             will be used to confirm patients have constipation.&#xD;
&#xD;
          3. Unable to withdraw all medications 48 hours prior to Visit 1; any medication that&#xD;
             alters GI transit including but not limited to laxatives, magnesium or&#xD;
             aluminum-containing antacids. prokinetics, erythromycin, narcotics, anticholinergics,&#xD;
             tricyclic antidepressants and SNRIs; analgesic drugs including opiates, NSAIDs, and&#xD;
             COX-2 inhibitors (Note: Tylenol is permitted), GABAergic agents and benzodiazepines.&#xD;
&#xD;
             Note: All other concomitant medications will be reviewed on a case by case basis by&#xD;
             the study physicians.&#xD;
&#xD;
          4. Clinical evidence (including but not limited to a clinically significant abnormal&#xD;
             physical exam, ECG or laboratory test result in the past medical record) or current&#xD;
             clinically significant abnormal physical exam or laboratory test result that could&#xD;
             indicate significant cardiovascular, respiratory, renal, hepatic, gastrointestinal,&#xD;
             hematological, neurological, psychiatric or other diseases that interfere with the&#xD;
             objectives of the study. If a laboratory test result is abnormal and clinically&#xD;
             significant, it may be repeated once at the discretion of the PI. If the laboratory&#xD;
             test result remains abnormal and clinically significant, the patient will be&#xD;
             discontinued from the study and referred to a primary care physician for further&#xD;
             evaluation.&#xD;
&#xD;
          5. Patients who are considered by the PI to be alcoholics not in remission or known&#xD;
             substance abusers.&#xD;
&#xD;
          6. Patients who have participated in another clinical study in the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials.</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011 Dec;106(12):2154-64. doi: 10.1038/ajg.2011.285. Epub 2011 Aug 30.</citation>
    <PMID>21876564</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <results_first_submitted>August 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <disposition_first_submitted>July 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 7, 2012</disposition_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Camilleri, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>functional constipation</keyword>
  <keyword>bile acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01038687/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A3309 15 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="P2">
          <title>A3309 20 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A3309 15 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="B2">
          <title>A3309 20 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="13"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="2.4"/>
                    <measurement group_id="B2" value="46.7" spread="1.9"/>
                    <measurement group_id="B3" value="47.5" spread="2.6"/>
                    <measurement group_id="B4" value="44.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="13"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="13"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonic Transit at 24 Hours</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
        <time_frame>24 hours post-radiolabeled meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit at 24 Hours</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.07"/>
                    <measurement group_id="O2" value="3.12" spread="0.07"/>
                    <measurement group_id="O3" value="1.93" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic filling was measured by scintigraphy as the percentage of the radiolabeled meal that reached the colon at 6 hours.</description>
        <time_frame>6 hours post-radiolabeled meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic filling was measured by scintigraphy as the percentage of the radiolabeled meal that reached the colon at 6 hours.</description>
          <units>percentage of colonic filling</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="9.3"/>
                    <measurement group_id="O2" value="60.0" spread="6.1"/>
                    <measurement group_id="O3" value="50.4" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying , T1/2</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Gastric emptying (GE t 1/2) was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the stomach.</description>
        <time_frame>post-treatment, approximately 12-14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying , T1/2</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Gastric emptying (GE t 1/2) was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the stomach.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.4" spread="14.4"/>
                    <measurement group_id="O2" value="159.4" spread="12.8"/>
                    <measurement group_id="O3" value="130.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascending Colon Emptying t 1/2</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Ascending colon emptying t 1/2 was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the ascending colon.</description>
        <time_frame>post-treatment, approximately 12-14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ascending Colon Emptying t 1/2</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Ascending colon emptying t 1/2 was measured by scintigraphy and defined as the time required for 50% of the radiolabeled tracer to empty from the ascending colon.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="3.6"/>
                    <measurement group_id="O2" value="5.8" spread="1.9"/>
                    <measurement group_id="O3" value="14.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit at 8 Hours</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
        <time_frame>8 hours post-radiolabeled meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit at 8 Hours</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.55"/>
                    <measurement group_id="O2" value="2.82" spread="0.55"/>
                    <measurement group_id="O3" value="1.20" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit at 48 Hours</title>
        <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
        <time_frame>48 hours post-radiolabeled meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit at 48 Hours</title>
          <description>Subjects ingested a Technetium-99m sulfur colloid radiolabeled meal and Indium-111 absorbed on to activated charcoal particles and delivered to the colon by an oral methacrylate-coated capsule. Colonic transit was measured by quantification of radioactive counts via abdominal scintiscans. Overall colonic transit was computed as the colonic geometric center (GC), which is the weighted average of counts in the different colonic regions (ascending, transverse, descending, rectosigmoid and stool), respectively numbered 1 to 5. At any time point, the GC equals the proportion of counts in each colonic region multiplied by its weighting factor: (%ACx1+%TCx2+%DCx3+%RSx4+%stoolx5)/100. As such, a higher GC reflects faster colonic transit. A GC of 1 implies all the isotope is in the ascending colon and a GC of 5 implies all the isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.07"/>
                    <measurement group_id="O2" value="3.91" spread="0.07"/>
                    <measurement group_id="O3" value="2.18" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>Subjects maintained a validated daily bowel diary and recorded the number of bowel movements each day during treatment.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Subjects maintained a validated daily bowel diary and recorded the number of bowel movements each day during treatment.</description>
          <units>bowel movements</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.15"/>
                    <measurement group_id="O2" value="2.14" spread="0.39"/>
                    <measurement group_id="O3" value="1.43" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency</title>
        <description>Subjects maintained a validated daily bowel diary during treatment and recorded stool consistency according to the Bristol Stool Form Scale, where: 1= separate hard lumps; 2= lumpy sausage-shape; 3= cracked sausage; 4= smooth and soft sausage; 5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency</title>
          <description>Subjects maintained a validated daily bowel diary during treatment and recorded stool consistency according to the Bristol Stool Form Scale, where: 1= separate hard lumps; 2= lumpy sausage-shape; 3= cracked sausage; 4= smooth and soft sausage; 5=soft blobs; 6=mushy, fluffy pieces; 7= watery, no solid pieces.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="0.32"/>
                    <measurement group_id="O2" value="4.42" spread="0.32"/>
                    <measurement group_id="O3" value="2.69" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Effectiveness of A3309</title>
        <description>Subject perception of treatment efficacy was measured using a 5 point numerical scale where 1=not at all effective to 5=extremely effective.</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A3309 15 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O2">
            <title>A3309 20 mg</title>
            <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Effectiveness of A3309</title>
          <description>Subject perception of treatment efficacy was measured using a 5 point numerical scale where 1=not at all effective to 5=extremely effective.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.3"/>
                    <measurement group_id="O2" value="2.4" spread="0.4"/>
                    <measurement group_id="O3" value="4.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>15mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>20mg dose vs placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected on each subject from enrollment until 7-10 days after the last day of the study medication, for approximately one month.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A3309 15 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="E2">
          <title>A3309 20 mg</title>
          <description>Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.&#xD;
A3309: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramps/pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Borboygmi</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomach upset</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoid pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lightheadness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Body ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Camilleri, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2305</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

